00:00It's Benzinga, bringing Wall Street to Main Street.
00:02Hims & Her's Health shares rose in Thursday pre-market trading after the company-backed
00:07FDA plans to clarify peptide therapy regulations and expand access, according to Bloomberg.
00:13Health Secretary RFK Jr. said the FDA will ease restrictions on peptide injections and
00:19review select peptides in July, with potential removal from the high-risk list. The company
00:24said this could shift treatments into regulated channels and open new revenue opportunities.
00:30It is exploring expansion aligned with FDA guidance. B of A Securities cut its price target
00:35to $21 and warned of 2026 EBITDA pressure as GLP-1 contribution declines. The analysts lowered
00:44GLP-1 revenue estimates and cited margin pressure from branded treatments and international mix.
00:51Shares rose 9.63% to $26.63 in pre-market trading on Thursday, according to Benzinga Prodata.
00:59For all things money, visit Benzinga.com.
Comments